Muscle Blood Flow Regulation in HFpEF
Recruiting · NCT05115890 · Interventional (participants receive a specific treatment) · Lead sponsor: VA Office of Research and Development
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System. Exercise intolerance is a common complication experienced by patients with HFpEF, perpetuating physical inactivity and accelerating disease progression. This research proposal aims to elucidate mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF compared with healthy controls as well as following 8 weeks of exercise training in patients with HFpEF only.
Who can take part
Inclusion criteria
- Age 18 years or older and able to give written informed consent
- New York Heart Association (NYHA) functional class II or III
- Left Ventricular Ejection Fraction (LVEF) \> 50%
- Plasma Brain Natriuretic Peptide (BNP) \>200 pg/mL or NT-proBNP 400 pg/mL at enrollment
Exclusion criteria
- Prior EF of \<50%.
- NYHA Class IV or HF that cannot be stabilized on optimized pharmacotherapy
- Acute coronary syndrome, infiltrative cardiomyopathy, or myocarditis
- Patients with HFpEF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction)
- Orthopedic limitations that would prohibit knee-extensor exercise
- Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT
- Women who are pregnant or may become pregnant, but the typical age of female patients with HFpEF will be postmenopausal
- Current smokers
Where it is running
1 location listed across 1 US state.
- VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City, Utah, United States